Venture Report: Megarounds for ArsenalBio, eGenesis

Two companies announced nine-digit venture rounds during the short holiday week, fortifying their balance sheets as they move products into clinical testing.

Arsenal Biosciences Inc. drew a $325 million series C round as it begins clinical testing of its second engineered CAR T therapy to treat solid tumors. The biotech’s AB-2100, entering Phase I for clear cell renal cancer, follows behind its AB-1015, already in the clinic for ovarian cancer...